| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Vesnarinone (OPC-8212) is a quinolinone-based cardiotonic agent, acting as a mixed phosphodiesterase 3 (PDE3) inhibitor and ion-channel modifier with modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure. Vesnarinone is also a novel cytokine inhibitor with the potential to be used for the treatment of lung fibrosis. Vesnarinone inhibits BLM-induced pulmonary fibrosis, at least in part, by the inhibition of acute lung injuries in the early phase.
| ln Vitro |
Vesnarinone suppresses cell proliferation in a dose-dependent manner (60 and 100 μg/mL; 48 hours) [3]. Apoptosis and G1 arrest are brought on by vesnarinone (60 μg/mL; 48 hours) [3]. After being treated for 0, 12, 24, and 48 hours with 60 μg/mL of vesnarinone, p21-mRNA expression was enhanced and p21 protein was marginally decreased [3].
|
|---|---|
| ln Vivo |
Rat liver is covalently bonded to vesnarinone (oral gavage; 300 mg/kg; once daily; 6 weeks) [4].
|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: OSC3, OSC4 and OSC5 Cell Tested Concentrations: 60 μg/mL and 100 μg/mL Incubation Duration: 48 hrs (hours) Experimental Results: More than 50% inhibition was observed in cells treated with 100 μg/mL, And MTT formazan production was diminished by 30±40% in cells treated with 60 μg/mL. Apoptosis analysis [3] Cell Types: OSC3, OSC4, OSC5 Cell Tested Concentrations: 60 μg/mL Incubation Duration: 48 hrs (hours) Experimental Results: The number of S-phase tumor cells diminished, and the number of G1-phase tumor cells increased. Western Blot Analysis [3] Cell Types: OSC3, OSC4 and OSC5 Cell Tested Concentrations: 60 μg/mL Incubation Duration: 0, 12, 24 and 48 hrs (hours) Experimental Results: p21-mRNA expression increased after 12±24 hrs (hours) of venalidone treatment. After 24 hrs (hours) of OSC4 treatment, p21 protein diminished slightly. |
| Animal Protocol |
Animal/Disease Models: Female Lewis rat (200 g) [4]
Doses: 300 mg/kg Route of Administration: po (oral gavage); 300 mg/kg; one time/day; 6 weeks Experimental Results: Covalently modified liver proteins were observed. |
| References |
[1]. A Matsumori, et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994 Mar;89(3):955-8.
[2]. E Cavusoglu, et al. Vesnarinone: a new inotropic agent for treating congestive heart failure. J Card Fail. 1995 Jun;1(3):249-57. [3]. K Yoneda, et al. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett. 1998 Nov 13;133(1):35-45. [4]. Iain Gardner, et al. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem Res Toxicol. 2005 Sep;18(9):1384-94. |
| Molecular Formula |
C22H25N3O4
|
|---|---|
| Molecular Weight |
395.459
|
| Exact Mass |
395.1845
|
| CAS # |
81840-15-5
|
| Related CAS # |
81840-15-5;
|
| SMILES |
O=C1NC2=C(C=C(N3CCN(C(C4=CC=C(OC)C(OC)=C4)=O)CC3)C=C2)CC1
|
| InChi Key |
ZVNYJIZDIRKMBF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H25N3O4/c1-28-19-7-3-16(14-20(19)29-2)22(27)25-11-9-24(10-12-25)17-5-6-18-15(13-17)4-8-21(26)23-18/h3,5-7,13-14H,4,8-12H2,1-2H3,(H,23,26)
|
| Chemical Name |
6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
|
| Synonyms |
RG-0210 OPC8212 PiteranometozineRG 0210 OPC 8212 VesnarinoneRG0210 OPC-8212 Arkin Arkin-Z.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~42.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (4.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (4.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5287 mL | 12.6435 mL | 25.2870 mL | |
| 5 mM | 0.5057 mL | 2.5287 mL | 5.0574 mL | |
| 10 mM | 0.2529 mL | 1.2644 mL | 2.5287 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
